PeptoPlus

← All products

SEMA
Approved medicine

Semaglutide

GLP-1 receptor agonist for long-term weight management.

Class
GLP-1 receptor agonist
Used for
Weight loss

Read the details Verify your code

Two adults in sportswear

Mode of action

  • Helps the body release insulin when blood sugar is high
  • Lowers appetite, so you eat less
  • Slows stomach emptying, mostly early in treatment

Purpose

Long-term weight management in eligible adults with obesity or overweight and a weight-related health problem.

Injection strengths (approved label)

0.25 mg/0.5 mL0.5 mg/0.5 mL1 mg/0.5 mL1.7 mg/0.75 mL2.4 mg/0.75 mL7.2 mg/0.75 mL*

*7.2 mg: certain markets and formulations only.

Route

Injection under the skin (subcutaneous). In the main trial: once a week, from 0.25 mg up to 2.4 mg by week 16.

Which receptors it switches on

ReceptorWhat it does
GLP-1Lowers appetite, slows stomach emptying, helps insulin releaseYes
GIPHelps insulin release and appetite and energy controlNo
GlucagonBeing studied for raising energy useNo

STEP 1: how many people lost weight

5% or more
86.4%
31.5%
10% or more
69.1%
12.0%
15% or more
50.5%
4.9%
20% or more
32.0%
1.7%
DrugPlacebo
14.9%average weight lost at 68 weeks (placebo: 2.4%)
15.3 kgaverage loss (placebo: 2.6 kg)
~2%developed gallstones in STEP 1

Source: STEP 1, 68 weeks, 1,961 adults without diabetes (NEJM 2021). Share of people reaching each weight-loss goal.

Side effects: what the trials showed

Common stomach effects in trials: nausea, vomiting, diarrhea and constipation. Doctors also check for dehydration, gallbladder disease and pancreatitis.

Source: WEGOVY prescribing information (DailyMed); STEP 1 (NEJM 2021). The label on every PeptoPlus unit hides a one-time code under a scratch layer, with a QR beside it. Scan it to check that the code was issued by PeptoPlus.